Brad Dahms

Brad Dahms is the Chief Financial Officer of Jade Biosciences. He brings over 15 years of financial and strategic leadership experience across the biotechnology and investment banking sectors, with a focus on corporate finance, capital markets, and business development.

Prior to joining Jade, Mr. Dahms was Chief Financial Officer and Chief Business Officer of IDRx, where he led financial operations, investor relations, and business development, including its transition to a public-ready company and sale to GSK for up to $1.15 billion. Before that, he served as Chief Financial Officer of Theseus Pharmaceuticals, where he guided the company’s initial public offering and sale to Concentra Biosciences. Earlier, Mr. Dahms was Chief Financial Officer at Selecta Biosciences, where he played a central role in securing several financings and leading multiple strategic partnerships.

Mr. Dahms began his career in healthcare investment banking, holding roles at Cantor Fitzgerald, RBC Capital Markets, and J.P. Morgan. He earned a B.S. in Economics, with honors, from The Ohio State University.